Media

DeepCure announced today the appointment of Dr. Han Lim as Chief Business Officer (CBO). Dr. Lim will lead all business development, portfolio planning, and corporate strategy functions at the company.

DeepCure, developer of small molecule therapeutics using an AI-enabled drug discovery platform, raised $40 million in Series A funding.

A Boston-based biotech company, DeepCure, announced the closing of its $40 million Series A financing round.

Series A financing will catalyze growth and advance novel small molecule therapeutics pipeline across various disease indications.

DeepCure, a Boston-based A.I. drug discovery company, raised $40 million in Series A funding. Morningside Ventures led the round and was joined by investors includingTLV Partners, Sapir Venture Partners, and Benon Group

Boston AI-focused biotech DeepCure closed a $40 million Series A — adding more than five times the amount of money the company had before.

DeepCure and other biotechs aim to accelerate drug discovery with artificial intelligence

MIT Startup Exchange is pleased to announce the addition of six companies to its roster of STEX25 startups. New additions to the program include: Amogy, DeepCure, E25Bio, OPT Industries, Pathr, and Sync Computing.